InvestorsHub Logo

lightrock

01/24/21 1:40 PM

#34996 RE: GD #34995

Ok, not to argue, but then we need to resolve this...

https://clinicaltrials.gov/ct2/show/NCT01265849?term=multikine&draw=2&rank=3


Primary Outcome Measures :
Overall Survival (OS) in LI + CIZ + SOC vs. SOC [ Time Frame: 3 year ]
OS will be assessed using Kaplan-Meier life-table and compared using a logrank test and confirmed further with tumor stage location and geographic stratified log rank tests. The unstratified logrank test constitutes the primary analysis. A two-sided p-value of 0.05 or less will be considered statistically significant for comparing the two groups. Interim analyses will be performed throughout the study to assess safety, sample size and futility.

lightrock

01/24/21 3:19 PM

#34997 RE: GD #34995

The regression thing at 3 year mark does something interesting, it eliminates magnification of small random "errors" that occur earlier on.

One event here can add up to a big difference the farther down the road you go, and it could be a statistical anomaly.

That's why the regression thing, it is more "proofy proof" of efficacy